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Abstract: 
Background: Endoscopic therapy, including by radiofrequency ablation 
(RFA) or endoscopic mucosal resection (EMR), is first line treatment for 
Barrett’s esophagus (BE) with high grade dysplasia (HGD) or intramucosal 
cancer (IMC) and may be appropriate for some patients with low grade 
dysplasia (LGD).  
Objective: To investigate the molecular effects of endotherapy. 
Methods: mRNA expression of 16 genes significantly associated with 
different BE stages was measured in paired pre-treatment BE tissues and 
post-treatment neo-squamous biopsies were obtained from 36 patients 
treated by RFA (19 patients, 3 IMC, 4 HGD, 12 LGD) or EMR (17 patients, 
4 IMC, 13 HGD). EMR was performed prior to RFA in 8 patients. Normal 
squamous esophageal tissues were from 20 control individuals.  
Results: Endoscopic therapy resulted in significant change towards the 
normal squamous expression profile for all genes. The neo-squamous 
expression profile was significantly different to the normal control profile 
for 11 of 16 genes.  
Conclusion: Endotherapy results in marked changes in mRNA expression, 
with replacement of the disordered BE dysplasia or IMC profile with a more 
“normal” profile. The neo-squamous mucosa was significantly different to 
the normal control squamous mucosa for most genes. The significance of 
this finding is uncertain but it may support continued endoscopic 
surveillance after successful endotherapy.  
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Abstract:  
Background: Endoscopic therapy, including by radiofrequency ablation (RFA) or 
endoscopic mucosal resection (EMR), is first line treatment for Barrett’s esophagus 
(BE) with high-grade dysplasia (HGD) or intramucosal cancer (IMC) and may be 
appropriate for some patients with low-grade dysplasia (LGD).  
 
Objective: To investigate the molecular effects of endotherapy. 
 
Methods: mRNA expression of 16 genes significantly associated with different BE 
stages was measured in paired pre-treatment BE tissues and post-treatment neo-
squamous biopsies from 36 patients treated by RFA (19 patients, 3 IMC, 4 HGD, 12 
LGD) or EMR (17 patients, 4 IMC, 13 HGD). EMR was performed prior to RFA in 8 
patients. Normal squamous esophageal tissues were from 20 control individuals. 
 
Results: Endoscopic therapy resulted in significant change towards the normal 
squamous expression profile for all genes. The neo-squamous expression profile 
was significantly different to the normal control profile for 11 of 16 genes. 
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Conclusion: Endotherapy results in marked changes in mRNA expression, with 
replacement of the disordered BE dysplasia or IMC profile with a more “normal” 
profile. The neo-squamous mucosa was significantly different to the normal 
control squamous mucosa for most genes. The significance of this finding is 
uncertain but it may support continued endoscopic surveillance after successful 
endotherapy.  
 
  
Page 4 of 26
htpp://mc.manuscriptcentral.com/UEGH
United European Gastroenterology Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 
Introduction  
Barrett’s esophagus (BE) is a premalignant condition in which the normal 
squamous lining of the lower esophagus is replaced by an intestinal metaplastic 
(IM) columnar epithelium in response to prolonged severe gastro-esophageal 
reflux. BE is the major risk factor for esophageal adenocarcinoma (EAC), a cancer 
with a high case fatality ratio and a rapidly rising incidence. The progression from 
normal esophagus to BE and adenocarcinoma is thought to involve a complex, 
multistep process, from IM to low-grade dysplasia (LGD), high-grade dysplasia 
(HGD), early intramucosal cancer (IMC), to invasive EAC.  
Intervention is recommended for patients with HGD or IMC, based on the 
estimated 7-19% yearly risk of EAC developing in patients with HGD.1 Endoscopic 
therapy has replaced esophagectomy as the preferred first-line treatment for most 
patients with HGD/IMC, as it avoids the morbidity and mortality associated with 
esophagectomy, preserves the esophagus, and has equivalent survival outcomes.2, 3 
Guidelines1, 4, 5 have recommended endoscopic mucosal resection (EMR) for visible 
lesions and radiofrequency ablation (RFA) of flat mucosae, including after EMR. 
Complete Barrett’s excision (CBE) endoscopic resection is an alternative for 
shorter Barrett’s segments.2 More recently, endoscopic therapy has been 
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recommended for patients with persistent and confirmed (by two expert GI 
pathologist, in two or more endoscopies) multifocal low-grade dysplasia.6, 7 
Eradication of cancer, dysplasia, and all BE is reported in up to 94% of patients 
treated with RFA or EMR,3, 8-10 The risk of EAC development is also significantly 
reduced.11 The rate of progression to EAC was one per 181 patient-years 
(0.55%/patient-years) in a multicenter US study, at three years after RFA or RFA 
and EMR combined treatment for dysplastic BE.8 In another study, the cancer-
related mortality rate was 0.2% in EMR treated patients with IMC after 5 years.3  
Although RFA and EMR have proven to be safe and effective in at least the medium 
term,9, 12, 13 there are reports of recurrence.13 The durability over decades, which is 
relevant for this disease, and underlying molecular effect, remains unknown. It has 
previously been shown that the altered mRNA expression of certain genes is 
associated with different stages of the Barrett’s to adenocarcinoma sequence.14 By 
comparing gene expression in the tissue biopsies of dysplastic Barrett’s or IMC 
mucosa before endoscopic therapy and in the normal-appearing neo-squamous 
mucosa post-treatment, we evaluated the molecular effect of endoscopic 
treatment.  
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Methods 
Patients 
Patients in the treatment group undergoing RFA, EMR, or combination of RFA plus 
EMR for the treatment of histopathologically confirmed BE with dysplasia or IMC 
were invited to participate in this prospective multi-center study. The treatment 
selected was at the discretion of the endoscopist. BE length was recorded using the 
Prague classification. Post-treatment biopsies were taken from the 
macroscopically normal appearing neo-squamous mucosa from the same area as 
the pre-treatment BE, as measured by distance from the incisors.   
A control group consisted of individuals with the typical reflux symptoms of 
heartburn or regurgitation but without a history of current or past macroscopic 
reflux esophagitis (RE) or Barrett’s esophagus (non RE/BE). Inclusion criteria for 
both groups were age ≥18 years and ability to give informed consent. Approval for 
the study was obtained from the Human Research Ethics Committee at each center 
and participants provided written informed consent.  
 
Endoscopic treatment 
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Radiofrequency ablation: After removal of visible lesions where present by EMR, 
the abnormal mucosa was ablated by RFA using either a circumferential balloon 
catheter or a flat plate device (BARRx Medical/Covidien, Inc., Sunnyvale CA). The 
RF energy was delivered to the Barrett’s mucosa (12 J/cm2, 40 W/cm2) twice in 
sequence. The device was removed and cleaned between applications, and the 
ablated epithelium was cleaned by irrigation or scrapped off with the edge of the 
device.  
Endoscopic mucosal resection: The irregular mucosa was resected using the 
Duette multiband mucosectomy system (Cook Medical, Bloomington, Ind). The 
mucosa is lifted by aspiration, ligated to form a pseudopolyp, and resected by 
electrocautery, as described previously.10 Both RFA and EMR were performed in 
single or multiple sessions, depending on the extent of BE. 
 
Tissue specimens 
From review of the histopathological reports of routine hematoxylin and eosin-
stained (H&E) tissue sections, archival formalin-fixed, paraffin-embedded (FFPE) 
esophageal tissue samples were obtained from the study centers. The worst 
histopathological grade of BE/IMC was selected for the pre-treatment dysplastic 
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BE or IMC study tissues. The post-treatment samples were matched neo-squamous 
mucosa collected from the same area as the previous BE mucosa.  
 
RNA Isolation 
Two 7 μm unstained sections cut from each FFPE sample block were used for RNA 
extraction. At least 55ng total RNA was isolated by a column-based purification 
method using the Ambion RecoverAllTM Total Nucleic Acid Isolation kit for FFPE, 
Cat # AM1975 (Life Technologies, Carlsbad, CA) or the QIAGEN RNeasy FFPE kit, 
Cat # 744404 (Qiagen, Valencia, CA), according to the manufacturer’s protocol. 
RNA purity and concentration was measured using a NanoPhotometer (Implen, 
Westlake Village, CA). 
 
mRNA quantification by multiplex tandem PCR (MT-PCR) 
Sixteen genes significantly differentially expressed at the mRNA level in BE and 
EAC compared to normal squamous esophagus were selected from previous 
studies.14, 15 Full details of the MT-PCR methods were reported previously.14 In 
brief, mRNA expression levels of the genes of interest and the internal reference 
gene, NONO ("non-POU domain containing, octamer-binding"; NM_007363), were 
measured in duplicate with pre- and post-treatment tissues assessed 
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simultaneously. MT-PCR was performed using a real time quantitative PCR system 
(Rotor-Gene RG6000, Qiagen, Valencia, CA). Primers for study genes and NONO 
were designed using Primer 3 software; the size of the “inner” amplicon was 
restricted to 70-90 bp and the “outer” amplicon to <150 bp. All primer pairs 
spanned an intron-exon boundary and the products were evaluated on a 
Bioanalyser DNA separation chip for the correct size (Agilent, Santa Clara, CA).  
MT-PCR was performed in two steps. In the first step the RNA was converted into 
cDNA and amplified using multiplexed gene specific primers (“outer” primers). In 
the second step the product from step one was used as a template for PCRs in a 72-
well disc containing lyophilized single-gene primers (“inner” primers) in each well. 
“Outer” primer mix was prepared by adding to one single tube 1 µL of each primer 
(forward and reverse) of all genes to 53 µL RNAse free diethylpyrocarbonate 
(DEPC) H2O to a total 125 µL, and they were lyophilized in 0.2 ml tubes. “Inner” 
primer mixes were prepared in different tubes (for each gene) by adding 4 μl of 
each primer (forward and reverse) into 424 μl of DEPC water.  
 
Statistical Analysis 
The mRNA relative expression values were measured as the ratio of the absolute 
expression values of each target gene to the expression of the reference gene 
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NONO, set to a fixed level (10000). Gene expression values were not normally 
distributed, and therefore are summarized as medians with the 25th-
75th interquartile range (IQR). 
To identify genes differentially expressed post-treatment compared to pre-
treatment values, unpaired (all subjects) and paired (subset of subjects with pre- 
and post-treatment samples) analyses were performed using the Wilcoxon rank-
sum and signed rank test respectively. The Wilcoxon rank-sum test was also used 
to compare gene expression in normal squamous control versus post-treatment 
neo-squamous. Fold change was calculated to describe the magnitude of the 
change in gene expression levels pre- and post-treatment. All data analyses were 
performed using the SAS software (version 9.3).  
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Results 
As shown in Table 1, 36 endotherapy patients (19 RFA, 17 EMR) and 20 control 
individuals were enrolled in the study. Most patients in both groups were male. In 
the RFA group, 8 patients (42%) underwent focal EMR before RFA to remove 
nodular lesions containing IMC (3 patients), HGD (4 patients) or LGD (1 patient). 
The remaining 11 patients were treated by RFA alone. In the EMR treatment 
group, five patients had CBE with complete eradication of BE in a single session; 
the remaining patients had stepwise EMR over more than one treatment session. 
Table 1 shows that EMR was performed for HGD or IMC, whereas the patients 
treated by RFA mostly (63%) had LGD in the untreated or post-EMR BE.  
Maximal BE length was 6 cm pre-RFA and 9 cm pre-EMR, with a median of 2 cm for 
both treatment groups, and RFA or EMR was performed in up to three sessions at 
2-3 month intervals. The median interval between the last treatment session and 
the post-treatment neo-squamous biopsy was 3 months for RFA and 6 months for 
EMR.  
At the time of neo-squamous biopsy for this study, 17 of 19 (89%) RFA treated 
patients and 14 of 17 (82%) EMR patients had complete eradication of dysplasia; 
with complete eradication of IM in 6/19 (32%) RFA and 10/17 (59%) EMR 
patients. Subsequent to the post-treatment study biopsy, dysplasia was eradicated 
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in all patients apart from one EMR patient who chose not to have further treatment 
because of advanced age, and IM has been eradicated in 58% and 88% of RFA and 
EMR patients, respectively. There was no sub-squamous BE in any of the neo-
squamous or normal squamous tissues.  
Twenty individuals were enrolled in the control group. Normal esophagus biopsies 
were obtained from the distal esophagus in 11 individuals and from the proximal 
(~25cm from incisors) esophagus in 9 individuals.  
Table 2 shows unpaired relative mRNA expression values for the 16 study genes in 
dysplastic Barrett’s or IMC pre-endoscopic treatment tissues and matched neo-
squamous tissue samples post-treatment in the 36 patients. Endoscopic therapy 
resulted in a highly significant change in median values for all 16 genes (Table 2). 
This was verified by paired analysis for patients with acceptable PCR results pre- 
and post endotherapy and the changes remained significant for all genes (data not 
shown). Ten genes were down-regulated and 6 genes were up-regulated in the 
normal neo-squamous mucosa after endoscopic treatment; all changes were from 
a Barrett’s-associated profile towards a normal squamous epithelium profile.  
Table 3 shows the relative gene expression levels in the neo-squamous epithelium 
compared to true normal squamous tissue from the 20 control individuals with 
GERD symptoms, but no RE/BE. The neo-squamous mucosa was significantly 
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different to true normal squamous mucosa for 11/16 (69%) genes. This difference 
was most marked for CD151, SPARC and TP73L (p <0.0001, shown graphically in 
Figure 1). Figure 1 also shows data for three genes with no significant difference 
between neo-squamous esophagus and true normal esophagus.  
Comparing neo-squamous biopsies taken less than 3 months post-treatment 
versus more than 3 months post-treatment, there was no significant difference 
found except that SPARC mRNA expression was significantly lower in the greater 
than 3 months follow-up tissue cohort (p 0.0159; data no shown)  
 
Discussion 
This study shows that there are marked changes in the relative mRNA expression 
levels of selected genes after RFA or EMR for the treatment of dysplastic BE or IMC. 
These changes are, as expected, towards a more “normal” squamous esophagus 
profile from non-BE patients. The mRNA expression in the neo-squamous mucosa 
post-treatment is not the same as found in the normal squamous mucosa, however, 
despite the neo-squamous mucosa being histopathologically indistinguishable 
from normal squamous epithelia.  
Our findings indicate molecular as well as macro- and microscopic reversal of BE 
by endoscopic therapy. The expression of genes which have previously shown to 
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be increased in a stepwise fashion from normal squamous esophagus to BE to EAC 
are significantly down-regulated by endotherapy, whereas those genes 
underexpressed in BE and EAC compared to normal mucosa are increased in 
expression after endotherapy. Although our study is the first to report mRNA 
expression changes, previous studies using different laboratory approaches have 
been reported.16 Pouw et al. found no abnormal immunohistochemical (IHC) 
expression for Ki-67 and p53, and no numerical chromosomal abnormalities in the 
neo-squamous epithelia of 22 patients successfully treated with RFA for HGD or 
IMC.17 Most of the patients (73%) in that study were treated with EMR before RFA 
for visible lesions, and salvage EMR was used on 18% of the patients after five RFA 
sessions to achieve complete eradication of BE. Krishnan et al., using IHC and 
Western blot methods, showed similar β-catenin expression in the neo-squamous 
and normal squamous mucosa at 12 months after successful RFA.18 Other studies 
have shown persistent genetic abnormalities in remnant BE after photodynamic 
therapy (PDT) or argon plasma coagulation (APC).19-21  
Comparing the gene expression profile of the neo-squamous mucosa with the 
normal squamous mucosa from individuals with typical reflux symptoms but no 
history of reflux esophagitis or BE, we found a significant difference for most 
genes. The relevance of this finding is unclear; we discuss three possible 
interpretations here. One interpretation is that this reflects ongoing wound 
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healing, although only a minority of our selected genes (such as COX-2, Matrix 
Metallopeptidases 1 and 7) is clearly involved in wound healing. There was also no 
important change in the findings when we compared early post-treatment results 
(<3 months after endotherapy) with later post-treatment results (>3 months), 
suggesting that wound healing does not explain our results.  
A second interpretation is that the differences in gene expression between the 
neosquamous and the normal squamous mucosa reflects a degree of molecular 
abnormality that is found even in the squamous mucosa in patients with BE. 
Brabender et al., for example, found a widespread carcinogenic field effect, 
measured in RNA quantification as in our study, in the normal squamous 
esophageal epithelia in patients with either BE or Barrett’s adenocarcinoma.22 In 
this respect the ideal design for our study would have included normal pre-
treatment squamous esophagus tissues from the patients with BE, but we lacked 
the biopsy samples to do this.  
A third interpretation is that patients with dysplastic BE/IMC retain some risk of 
disease persistence or recurrence, even after successful endoscopic therapy. This 
further suggests that ongoing surveillance after successful endotherapy is 
warranted, especially in younger patients. In keeping with this, Lewis et al. found 
raised cell proliferation (Ki-67) and COX-2 protein expression by IHC in buried 
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subsquamous glands after APC. They interpreted this finding as making it unclear 
whether the risk of cancer is adequately reduced by ablation, with potential 
implications for patient follow up.23 Similarly, Dijckmeester et al. found 
significantly higher expression of the microRNA-143 in neo-squamous after APC 
compared to normal squamous from control subjects, although expression of CK-8, 
CK-14, and microRNA-205 was similar.24 
Clinical studies also suggest the need for ongoing surveillance and optimal reflux 
control after endoscopic therapy. Disease recurrence has been reported after 
complete eradication of Barrett’s at variable rates. In a Netherlands cohort study, 
IM was present in 10% of patients treated with RFA after EMR for visible nodules 
at 5 years after treatment.25 Others report worse outcomes, including 33% BE 
recurrence rates at 2-years follow-up after EMR and RFA,12 5% recurrence of IM 
per year after RFA,26 and 14.5% recurrence of neoplasia (HGD or EAC) after 
approximately 2 years for EMR.3 Cancer can recur even five or more years after 
successful endotherapy.3 There are several clinical factors associated with worse 
response to endotherapy, including ongoing acid reflux exposure (which is usual in 
BE patients treated by PPIs), longer Barrett’s segment, and a longer history of 
dysplastic BE.27-29   
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Genetic biomarkers could play a role in predicting response to endoscopic 
treatment.16 A lower response to endoscopic treatment has been reported in 
patients with multiple chromosomal gains (gain of 2 or more locus-specific probes 
to MYC, p16, HER-2/neu and ZNF217, evaluated by fluorescence in situ 
hybridization (FISH)) in the dysplastic Barrett’s epithelium.30 After PDT, p16 allelic 
loss, also detected by FISH, was found to predict loss of dysplasia.31  
Our study was prospective, used biopsies evaluated by H&E (rather than an 
adjacent biopsy with unknown pathology), and by simultaneously running pre- 
and post- treatment biopsies we limited the possibility of a “batch effect”. Despite 
these methodological advantages, we acknowledge some limitations. Some neo-
squamous biopsies were obtained pre-complete BE eradication. Consequently, it is 
possible (but unknown) if the remnant BE may effect the gene expression of the 
neo-squamous mucosa. Our normal squamous samples also include biopsies at 
various levels above the gastroesophageal junction, which has been reported to 
influence gene expression,32 although there was no significant difference in 
expression in distal compared to proximal esophagus biopsies in our study (data 
not shown). We did not compare the mRNA expression changes after EMR 
compared to RFA because of the small number of patients in each group and the 
difference in severity of Barrett’s disease: most of the patients undergoing EMR 
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had IMC or HGD whereas patients undergoing RFA had mostly LGD (after EMR 
treatment of IMC or HGD in some cases).  
Our study found that the abnormal gene expression present at baseline in patients 
with dysplastic Barrett’s or IMC is altered after endotherapy towards a normal 
esophagus expression profile. This alteration was highly significant for all genes, 
indicating that the neo-squamous mucosa harbors a very greatly reduced 
malignant risk compared to untreated Barrett’s disease. This is consistent with the 
normal histopathological appearance of the neo-squamous mucosa and the 
reassuring results of clinical studies regarding the long-term cancer risk after 
endoscopic therapy. The neo-squamous mucosa was significantly different to the 
normal control squamous mucosa for most genes but the significance of this 
finding is uncertain. One interpretation is that it suggests that attention should be 
given to careful inspection of the neo-squamous mucosa as well as, of course, any 
persistent BE areas after endotherapy. This could include taking random biopsies 
from a normal appearing neo-squamous mucosa; although the benefit of this is 
disputed it can rarely uncover buried (sub-squamous) BE or even 
adenocarcinoma.17, 33-35 Altogether, we interpret our results as providing some 
support for long-term endoscopic surveillance after endoscopic treatment of 
BE/IMC, even if the BE has been completely eradicated, but we acknowledge that 
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more extensive studies with longer follow-up periods are needed to more 
thoroughly evaluate the neo-squamous mucosa.  
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Figure legends 
 
Figure 1. Endoscopic therapy resulted in significant changes in relative mRNA 
expression levels pre- and post-treatment for Barrett’s (BE) with dysplasia or 
intramucosal cancer, compared to true normal squamous mucosa from control 
individuals with reflux symptoms but no BE. (a) Neo-squamous mucosa is 
significantly different to normal (p <0.0001). (b) Neo-squamous mucosa is not 
significantly (ns) different to normal. Box plots show median (heavily longitudinal 
bar) and interquartile range (box). 
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Table 1. Patients, pathology and treatment data 
 
 RFA              
(n = 19) 
EMR           
(n = 17) 
No BE 
normal 
controls 
(n = 20) 
Sex – n (%)    
Males 17 (90%)  15 (88%) 17 (85%) 
Females  2 (10%) 2 (12%) 3 (15%) 
Age – years, median (range)  69 (52 - 84) 62 (31 – 82) 55 (33 – 77) 
Length of BE (Prague Classification)  
– cm, median (range) 
  
Circumferential (C) 0 (0 – 3)a 0 (0 - 5)  
Maximal (M) 2 (0.5 - 6)a 2 (0.5 - 9)  
Histological grade pre-treatment – n (%)    
Low-grade dysplasia 12 (63%)a  0 (0%)  
High-grade dysplasia 4 (21%)a 14 (76%)  
Intramucosal cancer 3 (16%)a 4 (24%)  
Median time, last treatment session to 
post-treatment biopsy (range), 
months 
3 (1 - 15) 6 (1 - 57)  
No. of treatment sessions - median 
(range) 
2 (1 - 3) 2 (1 - 3)  
RFA = Radiofrequency ablation, EMR = Endoscopic mucosal resection, BE = Barrett's 
esophagus 
a Pre-RFA, post-EMR wherever applicable. 
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Table 2. Difference in gene expression, pre- vs post-endoscopic treatment  
Gene 
Pre-treatment BE Post-treatment Neo-squamous 
p-valuea 
Fold 
change N Median expression (IQR) N Median expression (IQR) 
Downregulated         
TSPAN8 34 236.5  (8.9-2075.2) 25 3.8  (0.3-16.3) <0.0001 -62 
TSPAN1 36 13,219.4  (19.8-32268.7) 33 226.6  (1.5-574.8) 0.003 -58 
CTSE 36 15,185.0  (8383.0-23798.0) 18 402.9  (66.9-5434.8) 0.0001 -38 
MMP7 31 355.2  (127.2-556.7) 25 17.4  (4.5-73.7) <0.0001 -20 
MMP1 34 21.1  (9.2-92.3) 26 3.1  (1.1-5.7) <0.0001 -7 
COX-2 36 219.9  (92.7-559.3) 34 49.0  (19.8-159.2) 0.0005 -5 
ODC1 36 4,780.1 (3005.0-5798.1) 36 1,434.9  (1044.2-2109.0) <0.0001 -3 
CD151 36 1,657.6  (1241.8-2212.7) 33 574.8  (391.1-872.4) <0.0001 -3 
SPARC 36 15,177.1  (13566.4-36100.0) 36 5,180.1  (4206.4-11393.2) <0.0001 -3 
RARA 30 223.1  (131.3-283.7) 24 95.4  (69.1-154.5) 0.0004 -2 
Upregulated         
ADH7 36 43.45  (11.3-172.6) 36 556.7  (294.4-902.8) <0.0001 13 
KRT4 36 32,854.0  (12736.1-109360.5) 36 251,647.6  (134571.2-434243.6) <0.0001 8 
RARG 33 108.3  (55.2-212.6) 33 674.9  (430.1-930.3) <0.0001 6 
SERPINB2 33 53.5  (6.2-98.4) 36 261.9 (110.2-1349.9) <0.0001 5 
PITX1 36 3,252.2  (901.4-11746.6) 36 10,505.4  (6280.0-80569.9) <0.0001 3 
TP73L 33 8.1 (4.2-27.3) 35 23.0  (8.1-58.9) 0.02 3 
IQR = Interquartile Range, a Wilcoxon test 
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Table 3. Difference in gene expression: normal squamous vs neo-squamous 
Gene 
Normal squamous Neo-squamous 
p-valuea 
N Median expression (IQR) N Median expression (IQR) 
CD151 20 40.0  (12.4-141.3) 33 574.8  (391.1-872.4) <0.0001 
SPARC 20 1345.7  (259.7-3051.6) 36 5180.1  (4206.4-11393.2) <0.0001 
TP73L 20 246.6  (206.8-356.9) 35 23.0  (8.1-58.9) <0.0001 
PITX1 20 4458.0  (2770.1-8831.0) 36 10505.4  (6280.0-80569.9) 0.0002 
ADH7 20 1370.1  (598.7-2572.7) 36 556.7  (294.4-902.8) 0.001 
RARA 20 40.1  (14.3-90.9) 24 95.4  (69.1-154.5) 0.009 
MMP7 20 100.3  (33.7-199.2) 25 17.4  (4.5-73.7) 0.0095 
CTSE 12 37.8  (8.0-132.2) 18 402.9  (66.9-5434.8) 0.01 
SERPINB2 20 1395.4  (996.0-2953.7) 36 261.9  (110.2-1349.9) 0.01 
RARG 20 238.8  (153.5-598.5) 33 674.9  (430.6-930.3) 0.02 
MMP1 17 8.6  (2.7-34.1) 26 3.1  (1.1-5.7) 0.02 
TSPAN1 16 29.3  (5.2-60.1) 33 226.6  (1.5-574.8) 0.25 
TSPAN8 10 8.8  (5.4-15.4) 25 3.8  (0.3-16.3) 0.32 
ODC1 20 1370.1  (310.0-2147.3) 36 1434.9  (1044.2-2109.0) 0.33 
KRT4 19 281,526  (9455-737308) 36 251,647.6  (134571.2-434243.5) 0.41 
COX-2 20 51.9   (21.1-87.0) 34 49.0  (19.8-159.2) 0.73 
IQR = Interquartile Range, a Wilcoxon test 
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Figure 1. Endoscopic therapy resulted in significant changes in relative mRNA expression levels pre- and 
post-treatment for Barrett’s (BE) with dysplasia or intramucosal cancer, compared to true normal squamous 
mucosa from control individuals with reflux symptoms but no BE. (a) Neo-squamous mucosa is significantly 
different to normal (p <0.0001). (b) Neo-squamous mucosa is not significantly (ns) different to normal. Box 
plots show median (heavily longitudinal bar) and interquartile range (box).  
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